Weight trajectories through infancy and childhood and risk of non-alcoholic fatty liver disease in adolescence: The ALSPAC study  by Anderson, Emma L. et al.
Research ArticleWeight trajectories through infancy and childhood and risk of
non-alcoholic fatty liver disease in adolescence: The ALSPAC study
Emma L. Anderson1,2,⇑, Laura D. Howe1,2, Abigail Fraser1,2, Mark P. Callaway3, Naveed Sattar4,
Chris Day5, Kate Tilling1, Debbie A. Lawlor1,2
1MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; 2School of Social and Community Medicine,
University of Bristol, Bristol, UK; 3University Hospitals Bristol NHS Foundation Trust, UK; 4Institute of Cardiovascular & Medical Sciences,
BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, UK; 5Institute of Cellular Medicine,
Faculty of Medical Sciences, Newcastle University, UKBackground & Aims: Adiposity is a key risk factor for NAFLD.
Few studies have examined prospective associations of infant
and childhood adiposity with subsequent NAFLD risk. We exam-
ined associations of weight-for-height trajectories from birth to
age 10 with liver outcomes in adolescence, and assessed the
extent to which associations are mediated through fat mass at
the time of outcome assessment.
Methods: Individual trajectories of weight and height were esti-
mated for participants in the Avon Longitudinal Study of Parents
and Children using random-effects linear-spline models. Associa-
tions of birthweight (adjusted for birth length) and weight
change (adjusted for length/height change) from 0–3 months,
3 months–1 y, 1–3 y, 3–7 y, and 7–10 y with ultrasound scan
(USS) determined liver fat and stiffness, and serum alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), and
gamma-glutamyl transferase (GGT) at mean age 17.8 y were
assessed with linear and logistic regressions. Mediation by con-
current fat mass was assessed with adjustment for fat mass at
mean age 17.8 y.
Results: Birth weight was positively associated with liver stiff-
ness and negatively with ALT and AST. Weight change from birth
to 1 y was not associated with outcomes. Weight change from 1–
3 y, 3–7 y, and 7–10 y was consistently positively associated with
USS and blood-based liver outcomes. Adjusting for fat mass at
mean age 17.8 y attenuated associations toward the null, sug-
gesting associations are largely mediated by concurrent body
fatness.Journal of Hepatology 20
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Non-alcoholic fatty liver disease (NAFLD) is one of the most com-
mon causes of chronic liver disease in children and adolescents in
the developed world [1,2], and is associated with ﬁbrosis, insulin
resistance, and dyslipidaemia, independently of total body fat [3].
Greater adiposity is a key risk factor for NAFLD; previous studies
have reported NAFLD prevalences of up to 80% in obese children
[4], as well as cross-sectional associations of BMI in childhood
and adolescence with NAFLD [5–7]. Prospective studies assessing
associations of adiposity, or rates of change in adiposity through-
out infancy and childhood with NAFLD at a later age are lacking.
Such studies are important for establishing the age at which
these associations emerge. Furthermore, understanding associa-
tions of change in adiposity across infancy and childhood with
later NAFLD is important for establishing whether there are
sensitive periods for the development of NAFLD.
Previous studies suggest that infancy is a sensitive period in
the relationship between increasing weight and later cardiomet-
abolic risk [8–10]. However, more recent evidence from the
ALSPAC cohort suggests that weight gain most proximal to the
cardiometabolic outcomes is more strongly associated with these
outcomes compared with weight gain earlier in life [11,12]. One
previous study reported positive associations of conditional
weight growth from ages 0–11 years with NAFLD outcomes, with
associations from age 2 years attenuating after adjustment for
adult BMI [13]. Another study reported a higher prevalence of
NAFLD in children born small for gestational age who experi-
enced rapid catch-up growth in the ﬁrst year of life, compared
to appropriate for gestational age controls [14].
The aims of this study were: (i) to assess associations of BMI
at different time-points between birth and age 10 years with14 vol. 61 j 626–632
1887 included in USS sub-study who 
completed USS examination
Eligible USS sample
n = 1827 participants who have USS data 
available and have a measure of height 
and weight between birth and 120 mo
USS data available
• USS liver fat: n = 1669
• USS liver stiffness: n = 1675
3188 with available biomarker data from 
17-18 yr follow-up
Eligible blood-based outcome sample
n = 3106 participants who have biomarker 
data available and a mesure of height and 
weight between birth and 120 mo
Blood-based outcome data available
• ALT: n = 3106
• AST: n = 3106
• GGT: n = 3105
14,273 singleton pregnancies
13,678 singletons still alive at age 1-yr
5081 attended the 17-18 yr follow-up clinic
Fig. 1. Participant ﬂow through the study. Participants were excluded if they had no weight or height measures between birth and 10 years or they had harmful alcohol
consumption.
JOURNAL OF HEPATOLOGYmarkers markers of NAFLD (USS determined liver fat and stiffness
[a marker of ﬁbrosis] and blood-based indicators of liver func-
tion; alanine aminotransferase (ALT), aspartate aminotransferase
(AST) and gamma-glutamyl transferase (GGT)) at mean age
17.8 years, (ii) to assess associations of trajectories of weight
change, adjusted for height change, from birth to age 10 years
with markers of adolescent NAFLD and (iii) to examine the extent
to which any observed associations in change in adiposity
between birth and age 10 are mediated through fat mass at the
time outcomes were assessed.Materials and methods
Study population
ALSPAC is a population-based, prospective birth cohort from southwest England
(www.alspac.bris.ac.uk). Full details of the study have been published previously
[15,16]. Ethical approval for the study was obtained from the ALSPAC Ethics and
Law Committee and Local Research Ethics Committees. Five-thousand and eighty-
one singletons attended a 17–18 year follow-up assessment (mean age
17.8 years) and of these, 3188 [62.7%] had data available for blood-based indica-
tors of liver function including ALT, AST, and/or GGT. A liver USS sub-study was
undertaken on a sub-group of participants attending the 17–18 year follow-up.
Sub-study participants were a quasi-random group of those attending the
17–18 year follow-up in that the sub-study began 10 months after the general
follow-up and only participants who attended the general follow-up assessment
on a day that one of the trained sonographers was working were included. A total
of 1887 sub-study participants completed the USS examination (Fig. 1). Sub-study
participants are representative of the ALSPAC cohort [3]. Participants’ alcohol
consumption was assessed by questionnaires at the 16–17 year and 17–18 year
follow-ups, using the Alcohol Use Disorders Identiﬁcation Tests (AUDIT)
questionnaire [17]. Participants answered 10 questions about their alcohol con-
sumption, and from their responses, a score between 0 and 20 was derived. A
score over 16 is classiﬁed as harmful alcohol consumption [17]. Thirteen partici-
pants who completed the USS examination and 29 participants with blood-based
liver outcomes scored greater than 16 at both ages and were excluded from this
study. No participants had a known history of jaundice or hepatitis, were taking
medications or receiving treatment that would indicate they had hepatic disease,
or were taking medication known to inﬂuence liver function.Journal of Hepatology 201Assessment of outcomes
Participants attending the 17–18 year clinic in the morning were instructed to
fast overnight or for a minimum of 6-h, for those attending after lunch.
USS assessment of liver fat and stiffness
Assessment of USS liver fat and stiffness. The protocol for USS assessment in
ALSPAC has been published previously [3]. Brieﬂy, upper abdominal USS was
completed by one of four trained sonographers using a Siemens Acuson S2000
USS system. Echogenicity, our marker of liver fat, was assessed during deep inspi-
ration and recorded as present, absent or uncertain according to established pro-
tocols [18,19]. A longitudinal image, in the sagittal plane, with juxta position of
the right lobe of the liver and the right kidney was viewed and echogenicity
determined by comparison between the liver and kidney. Levels of agreement
in identifying echogenicity between the four sonographers was 98% or greater,
both immediately after training and at 6-month intervals throughout data collec-
tion. Acoustic radiation force impulse-imaging (ARFI) of the right lobe of the liver
was used to measure liver stiffness (our main indicator of liver stiffness), using
standard protocols [20,21]. ARFI, measured as shear velocity in meters/second
(m/s), was assessed six times with a gap of at least 1 min between each measure-
ment. The highest and lowest of these measurements were excluded and the
Siemens Acuson S2000 system produced a mean of the remaining four measure-
ments. If this mean was greater than four m/s, a further six measurements were
taken from the left lobe. When both right and left lobe values were available, the
lowest mean of the two has been used in analyses.
Assessment of blood-based indicators of liver function. Fasting blood samples were
immediately spun and frozen at 80 C. Measurements were assayed shortly (3–
9 months) after samples were taken with no previous freeze-thaw cycles. All
assays were completed in the same laboratory at the University of Glasgow.
ALT, GGT, and AST were measured by automated analyser with enzymatic meth-
ods. We deﬁned those with a value of >30 U/L ALT as having abnormally high ALT
levels, using the most common blood-based indicator and the threshold that has
been used previously in adolescent/childhood populations [22]. All inter- and
intra-coefﬁcients of variation for these blood-based assays were <5%.
Assessment of exposures and covariables. Length/height and weight data are avail-
able from several sources in ALSPAC at birth and throughout infancy and child-
hood. Full details of these measurements are provided in the Supplementary
data. Potential confounders considered in this analyses are as follows: age at
outcome assessment, gender, gestational age, breastfeeding at age 3 months,
parity, maternal age at the delivery, maternal pre-pregnancy smoking status4 vol. 61 j 626–632 627
Table 1. A description of characteristics for the USS and blood-based liver outcomes datasets.
USS dataset (n = 1827) Blood-based outcomes dataset (n = 3106)
N with data Distribution N with data Distribution
% USS liver fat 1669 2.6% n.a. n.a.
Males 1827 41.5% 3106 48.1%
Age 1827 17.93 (0.43) 3106 17.78 (0.40)
Weight at 17 1773 67.1 (14.10) 3027 67.37 (13.21)
Height 1771 1.71 (0.09) 3025 1.72 (0.09)
BMI 1771 22.98 (4.27) 3024 22.72 (3.91)
% Overweight 1771 16.7% 3024 16.3%
% Obese 1771 7.2% 3024 5.3%
Triglyceride 1268 0.83 (0.35) 3070 0.84 (0.36)
Insulin 1250 8.78 (9.49) 3039 8.31 (8.09)
Glucose 1268 5.05 (0.67) 3070 5.04 (0.60)
AUDIT score at outcome assessment 1452 6.88 (4.87) 2572 6.89 (4.63)
Non-white participants 1660 4.64 2841 4.36
Predicted birth weight 1827 3.40 (0.48) 3106 3.41 (0.49)
Predicted birth length 1827 50.73 (1.52) 3106 50.87 (1.55)
n.a., not available.
Research Articleand alcohol consumption, and household social class. Fat mass and height at age
17.8 years were considered as potential mediators. At the 17–18 year follow-up
visit, a Lunar prodigy narrow fan beam densitometer was used to perform a
whole body dual-energy X-ray absorptiometry (DXA) scan, from which total fat
mass was measured. Height was measured to the nearest 0.1 cm using a Harpen-
den stadiometer with the participant unshod. The assessment of all potential con-
founding variables is described in detail in the Supplementary data.
Statistical analyses
Estimating weight and height change trajectories from birth to 10 years. Individual
weight and length/height trajectories from birth to 10 years were estimated using
linear spline multilevel models, ﬁtted in MLwiN version 2.25 using the Stata
(StataCorp, College Station, Texas) command ‘runmlwin’ [23,24]. They were esti-
mated for all participants with at least one available weight and height measure
between these ages, under a missing at random (MAR) assumption. In our study,
birth weight (in kilograms) and length (in centimeters), and the rate of linear
weight change (in kilograms/year) and length/height change (in centimeters/
year) from birth to 3 months, 3 months to 1 year, 1 to 3 years, 3 years to 7 years,
and 7 years to 10 years were estimated [25]. This pre-pubertal age range was
selected to avoid the difﬁculty of being able to separate an effect of adiposity
change from an effect of puberty, which has major inﬂuences on weight/adiposity
change, and to provide a clear separation between the exposures and outcomes.
Full details of the weight and length/height models have been published previ-
ously [25] and are available on request.
Infant and childhood body mass index (BMI). The trajectories described above were
used to predict each participant’s height and weight at ages 3 months and 1, 3, 7,
and 10 years. BMI was calculated at these ages as predicted weight divided by
predicted height in meters-squared. BMI was standardised by sex to internal z-
scores.
Associations of BMI and weight-for-height change trajectories with liver outcomes.
ALT, AST, GGT, and liver stiffness were positively skewed and their natural logged
values were used in all linear regression analyses. Coefﬁcients from regression
models including these logged variables as outcomes were back transformed
and are interpreted as the percentage change in each outcome per standard devi-
ation increase in the exposure. Logistic or linear regression models examined
associations of infant and childhood BMI and weight-for-height trajectories with
measures of liver health at mean age 17.8 years.
Associations of BMI with liver outcomes were examined using the follow-
ing models: (1) unadjusted and (2) adjusted for all potential confounders.
Associations of weight trajectories with the liver outcomes were adjusted for
length/height trajectories to ensure any observed associations were due to
greater relative adiposity, rather than greater weight as a result of greater628 Journal of Hepatology 201height. Associations of weight trajectories with the liver outcomes were exam-
ined in the following models: (1) unadjusted; (2) adjusted for length or length/
height change in the same period as the weight or weight change exposure
(e.g., for associations where weight change from 3–7 years is the exposure,
height change from 3–7 years is adjusted for); (3) additionally adjusted for
all potential confounders. Breastfeeding is not adjusted for when birth weight
is the exposure variable as it occurs after the exposure and therefore cannot
confound these associations; (4) same as model 3 with additional adjustment
for potential confounding by all previous weight and length change; and (5)
same as model 4 with additional adjustment for DXA determined fat mass,
height and height-squared, assessed at the same time as the liver outcomes.
Model 5 examines potential mediation of associations of weight-for-height
change throughout infancy and childhood with liver outcomes by concurrent
total body fat. Likelihood ratio tests were used to check for gender interactions
in all models.
Dealing with missing data and additional analyses. Thirty four percent (n = 619/
1827) of eligible participants with USS data, and 25% (n = 790/3106) of eligible
participants with blood-based liver outcomes had missing data for some potential
confounders and outcomes (missing data for any one characteristic varied from
0.01% to 13%; Supplementary Tables 1 and 3). To minimise selection bias and
increase efﬁciency, multivariate multiple imputation was used to impute missing
data for potential confounders and outcomes for eligible participants in the two
separate samples. Full details of this procedure are provided in the
Supplementary data. Details of a series of sensitivity analyses that were
conducted to verify our statistical model assumptions and test the robustness
of our ﬁndings are also provided in the Supplementary data.Results
Prevalence of USS fatty liver was 2.5% in males (n = 17/685) and
2.6% in females (n = 26/958). ALT was elevated (>30 U/L) in 10.4%
of males (n = 156/1495) and 4.5% of females (n = 73/1611).
Table 1 provides a description of various characteristics the USS
and blood-based liver outcomes imputed datasets. A previous
publication provides a comparison of these characteristics
between those who do and do not have USS identiﬁed liver fat,
and details the prevalence of ﬁbrosis in the subgroup with
USS data [3]. Supplementary Tables 1 and 2 compare distribu-
tions of participant characteristics in the imputed and observed
data.4 vol. 61 j 626–632
Table 2. Associations of infant and childhood BMI with USS liver fat and liver
stiffness in the imputed data (n = 1827).
Age and confounder adjusteda
USS liver fat Odds Ratio 95% CI p value
BMI at age 3 months 1.11 (0.83,1.49) 0.47
BMI at age 1 year 1.00 (0.73,1.36) 1.00
BMI at age 3 years 1.31 (0.97,1.75) 0.08
BMI at age 7 years 2.01 (1.56,2.59) <0.01
BMI at age 10 years 2.28 (1.78,2.92) <0.01
USS liver stiffness % Change 95% CI p value
BMI at age 3 months +1% (0%,+2%) 0.01
BMI at age 1 year 0% (-1%,+1%) 0.70
BMI at age 3 years +1% (0%,+2%) 0.05
BMI at age 7 years +3% (+2%,+4%) <0.01
BMI at age 10 years +3% (+2%,+4%) <0.01
Coefﬁcients are per 1 standard deviation (SD) increase in BMI at ages 3 months
and 1, 3, 7, and 10 years. The SDs for BMI at each age are as follows: BMI at age
3 months = 1.43 kg/m2; BMI at age 1 year = 1.40 kg/m2; BMI at age 3 years =
1.11 kg/m2; BMI at age 7 years = 1.58 kg/m2; BMI at age 10 years = 2.64 kg/m2.
aAdjusted for age of the study child at the outcome assessment and potential
confounding by gender, gestational age, breastfeeding at age 3 months, parity,
maternal age at the birth of the study child, maternal pre-pregnancy smoking
status and alcohol consumption and household social class.
n.a., not available.
Table 3. Associations of infant and childhood BMI with ALT, AST, and GGT in
the imputed data (n = 3106).
Age and confounder adjusteda
ALT % Change 95% CI p value
BMI at age 3 months 0% (-2%,+1%) 0.76
BMI at age 1 year +1% (-1%,+2%) 0.28
BMI at age 3 years +3% (+1%,+4%) <0.01
BMI at age 7 years +6% (+5%,+8%) <0.01
BMI at age 10 years +8% (+6%,+9%) <0.01
AST % Change 95% CI p value
BMI at age 3 months -1% (-2%,0%) 0.10
BMI at age 1 year 0% (-1%,+1%) 0.90
BMI at age 3 years +1% (0%,+2%) 0.10
BMI at age 7 years +1% (0%,+2%) 0.01
BMI at age 10 years +1% (0%,+2%) 0.01
GGT % Change 95% CI p value
BMI at age 3 months -1% (-3%,+1%) 0.30
BMI at age 1 year 0% (-2%,+2%) 0.79
BMI at age 3 years +2% (0%,+4%) 0.13
BMI at age 7 years +4% (+2%,+6%) <0.01
BMI at age 10 years +5% (+3%,+8%) <0.01
Coefﬁcients are per 1 standard deviation (SD) increase in BMI at ages 3 months
and 1, 3, 7, and 10 years. The SDs for BMI at each age are as follows: BMI at age
3 months = 1.42 kg/m2; BMI at age 1 year = 1.37 kg/m2; BMI at age 3 years =
1.09 kg/m2; BMI at age 7 years = 1.51 kg/m2; BMI at age 10 years = 2.52 kg/m2.
aAdjusted for age of the study child at the outcome assessment and potential
confounding by gender, gestational age, breastfeeding at age 3 months, parity,
maternal age at the birth of the study child, maternal pre-pregnancy smoking
status and alcohol consumption and household social class.
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Fig. 2. Associations of weight-for height change from birth to 10 years with
USS liver fat in the main confounder adjusted model (circular dots) and the
model additionally adjusting for potential mediation by concurrent fat mass
(diamond dots), in the imputed data (n = 1827). Coefﬁcients are odds ratios for
USS liver fat per 1 standard deviation (SD) increase in birth weight or rate of
weight change in each age period of childhood (markers placed at the end of each
period of childhood).
JOURNAL OF HEPATOLOGYAssociations of infant and childhood BMI with liver outcomes
Point estimates for associations between BMI and both the USS
and blood-based liver outcomes increased with age at measure-
ment (Tables 2 and 3). For example, odds of having USS liver
fat per standard deviation increase in BMI increased from 1.31
(95%CI: 0.97–1.75) at age 3 to 2.28 (95%CI: 1.78–2.92) at age
10, and the percentage change in ALT per standard deviation
increase in BMI increased from +3% (95%CI: +1% ± 4%) at age 3
to +8% (95%CI: +6% ± 9%) at age 10.
Associations of weight-for-height trajectories from birth to 10 years
with liver outcomes
Birth weight-for-length was positively associated with liver stiff-
ness but not with liver fat, and negatively associated with ALT
and AST. There was no evidence for associations of weight-for-
length change from birth to age 1 with any of the liver outcomes.
Weight-for-height change after age 1 year was positively associ-
ated with all liver outcomes, except that weight-for-height
change from ages 7–10 was not associated with AST. Associations
of weight-for-height trajectories with USS liver fat and ALT in the
main confounder adjusted model (model 4) are presented in
Figs. 2 and 3, respectively. Associations of weight-for-height tra-
jectories with all other USS and blood-based liver outcomes (in
all models) are presented in Supplementary Tables 3 and 4.
Mediation by fat mass at the time of outcome assessment
After additional adjustment for total body fat mass at the time
liver outcomes were assessed, all associations attenuated toward
the null, though some associations remained. Results of this
model (model 5) are presented for liver fat and ALT in Figs. 2
and 3 respectively.Journal of Hepatology 201Gender differences
There was statistical evidence of a gender interaction for associ-
ations of weight-for-length/height change in some periods with
some, but not all outcomes. However, there was no consistent
pattern and in all cases, the direction of the associations for males
and females was the same, with only the magnitudes differing
(results available on request).4 vol. 61 j 626–632 629
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Fig. 3. Associations of weight-for-height change from birth to 10 years with
ALT in the main confounder adjusted model (circular dots) and the model
additionally adjusting for potential mediation by concurrent fat mass
(diamond dots), in the imputed data (n = 3106). Coefﬁcients are per 1 standard
deviation (SD) increase in birth weight or in the rate of weight change in each age
period of childhood (markers placed at the end of each period of childhood).
Research ArticleAdditional analyses
Results were similar when restricted to participants with com-
plete data on all variables included in the analysis, when
restricted to participants that had at least 2 measures of weight
and height from birth to 10 years, and when restricted to partic-
ipants with a measure of weight and height in each age period
deﬁned by our linear spline model. Results were also very similar
after additional adjustment for AUDIT scores, and when using
ponderal index instead of BMI. We found no evidence of an inter-
action with birthweight (i.e., no evidence that associations of
weight change from birth to 10 years with the liver outcomes dif-
fer for those in the lowest tertile of birth weight compared to
those in the upper two tertiles). Results from all additional anal-
yses are available on request.Discussion
In this study we assessed prospective associations of BMI at dif-
ferent ages in infancy and childhood, and of trajectories of
weight-for-height change from birth to age 10 years, with mea-
sures of liver health in adolescence. BMI at ages 7 and 10 years
were consistently positively associated with all liver outcomes,
whilst associations of BMI at younger ages differed by age and
outcome. Using weight-for-height trajectories as exposures, we
found that rates of weight-for-height change between ages 1
and 10 years were consistently positively associated with both
USS and blood-based outcomes, whereas associations of birth
weight-for-length and weight-for-length change in the ﬁrst year
of life were generally weak and inconsistent. Thus, our results
suggest that greater adiposity gain (assessed by weight-for-
height change) in childhood, particularly from age 3 years of
age, and higher BMI at age 7 and 10 years are importantly and
consistently associated with a range of different USS and blood-
based markers of liver damage in adolescence. Interventions to
limit adiposity gain from early in childhood are likely to be
important to prevent future adolescent, and potentially adult,
adiposity related liver disease.
Although infancy has previously been suggested as a sensitive
period for associations between greater adiposity and later630 Journal of Hepatology 201adverse cardiometabolic risk factors, our ﬁndings do not support
this; we found there were no consistent associations of BMI in
infancy with the liver outcomes. Our ﬁnding that rates of change
in adiposity between 1 and 10 years are consistently positively
associated with the liver outcomes, with increasing coefﬁcient
magnitudes throughout childhood, suggests there is no sensitive
period when greater rates of adiposity change is particularly det-
rimental and that greater increases in adiposity between ages 1
and 10 years might increase risk of NAFLD in adolescence. From
a public health perspective, this study highlights the need to con-
trol weight/fat gain at young ages in order to limit total body fat
and the risk of NAFLD in adolescence.
Comparisons with other studies
Cross-sectional studies have shown that greater BMI (and other
measures of adiposity) in childhood and adolescence is associated
with greater risk of NAFLD assessed by USS [26], blood-based
indicators [5–7,26], biopsy [27], and at post-mortem [1,28]. Con-
sistent with a previous study of adult women, (mean age
68 years, n = 2106) we found greater birth weight to be associ-
ated with lower ALT and AST levels [29]. Other studies of both
adults and children have reported no association between birth
weight and ALT [5,30]. Our ﬁnding that birth weight is positively
associated with USS liver fat and ﬁbrosis is inconsistent with the
inverse association with ALT and AST, and with what we might
expect from the developmental origins literature, which suggests
poor intrauterine nutrition results in a lower birth weight and
adverse development of the liver and other organs [31,32]. Stud-
ies using more direct assessments of liver pathology have
reported a strong and graded inverse relationship between birth
weight and length and mortality from cirrhosis [33], and associ-
ations of small for gestational age with increased risk of subse-
quent NAFLD [14,34]. Another study found several measures of
birth and childhood body size to be inversely related to NAFLD
outcomes in a group of 1587 individuals from the Helsinki Birth
Cohort. Similar to our ﬁndings, the same study also reported posi-
tive associations of conditional weight growth from 2 to 11 years
with NAFLD outcomes, however, once adult BMI was adjusted for,
coefﬁcients became negative [13].
Strengths and limitations
Our study was undertaken in a large contemporary cohort of ado-
lescents and we were able to adjust for a wide range of potential
confounders. The extent of repeat height and weight measure-
ments in our study means we were able to assess whether there
are any speciﬁc periods of development where rates of adiposity
change are particularly strongly associated with indicators of
NAFLD for the continuously measured outcome. However, we
acknowledge that power for the binary outcome of USS NAFLD
was limited due to the small number of cases. That said, results
were generally consistent for all outcomes. Advantages of using
multilevel models to obtain trajectories of weight and length/
height have been described in detail in a previous publication
[25].
USS is not the ‘gold standard’ for identifying NAFLD, how-
ever, it is neither feasible nor ethical to undertake liver biopsies
in large cohorts of healthy people. Studies have shown USS to
accurately identify moderate to severe steatosis compared with
liver biopsy in adults and children [35,36] and this has been4 vol. 61 j 626–632
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summarised in a systematic review and meta-analysis [37].
Thus, our prevalence estimate for NAFLD may reﬂect the moder-
ate to severe end of the spectrum of this disease. The ARFI mea-
sure of liver stiffness used in our study is a relatively new
measure, but has been validated in a small number of clinical
studies [38,39]. In models where we adjust for potential medi-
ation by fat mass at the time of outcome assessment, there is
potential for collider bias to occur [40]. This means that adjust-
ing for a potential mediator can introduce residual confounding
between the exposure and the outcome, if there are unadjusted
confounders of the mediator-outcome relationship. In this
study, the most plausible confounders of the fat mass-NAFLD
association are diet and physical activity. We were unable to
adjust for these, because they were not measured at age 17.
Evidence from a recent study suggests that, in practice, this gen-
erally does not result in considerable bias [41]. The MAR
assumption underlying our linear-spline models is likely to hold
in our example; results were similar in the complete-case anal-
ysis and when analyses were repeated on individuals with two
or more weight and length/height measures or at least one
measure per linear-spline period. This cohort is largely white
European (+96%) and we cannot assume results necessarily gen-
eralize to other ethnic groups. We were unable to examine
change in other measures of adiposity (such as DXA determined
total (or trunkcal) fat mass or waist circumference) with liver
outcomes in this study as these measurements were not under-
taken in infancy and early childhood in ALSPAC. However, our
earlier publication shows the relationships of BMI, DXA deter-
mined total and trunkcal fat mass with hepatic outcomes are
similar [42]. In this study we used AUDIT to assess alcohol con-
sumption in all participants. Although AUDIT has been validated
in adolescents, it is possible that participants may misreport
their alcohol consumption and that some NAFLD cases might
be alcohol-related. However, this is unlikely, ﬁrstly because
alcohol-induced steatosis requires high levels of alcohol con-
sumption for a prolonged period of time, which is less likely
to occur at age 17–18 years than at older ages, secondly because
we used a validated tool to remove those with harmful con-
sumption over the 12 months prior to liver assessment, and
additionally adjusted for the continuous AUDIT scores with very
little change to the results, and ﬁnally because our previous
publication shows the majority of NAFLD cases to be at the
upper end of the fat mass distribution [3].Conclusions
In conclusion, our results suggest that greater adiposity gain from
1 year of age is associated with adverse levels of a range of USS
and blood-based markers of liver disease, and that these associa-
tions are likely mediated through concurrent adiposity at the
time of outcome assessment. Since our study was conducted in
healthy participants with no known evidence of liver disease
and in whom those with persistent high levels of alcohol con-
sumption over the previous 12 months were removed, our study
supports initiatives aimed at promoting healthy growth and adi-
posity gain from early childhood to prevent NAFLD in adoles-
cence/young adulthood. Future randomised controlled trials of
interventions for limiting adiposity gain in childhood would
also be valuable in assessing the effect on NAFLD risk in
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